BriaCell gains on safety review of breast cancer therapy study

Briacell Therapeutics

24/06/2025 13:20

** U.S.-listed shares of BriaCell Therapeutics BCTX.O rise 4.2% to $3 premarket

** Co says an independent monitoring committee identified no safety concerns for its therapy Bria-IMT

** Committee recommends that BCTX continues its late-stage study of the therapy in patients with a form of breast cancer without any changes

** Review marks a third safety recommendation for BCTX to continue its study

** As of last close, BCTX down 66% YTD

 (Reporting by Bhanvi Satija in Bengaluru)

 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))